Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Recs

0
Player Avatar wofaintagain (30.22) Submitted: 10/15/2009 12:34:34 PM : Underperform Start Price: $3.22 DYAX Score: +67.94

until drug approval

Featured Broker Partners


Advertisement